Patents by Inventor Ian R. Hardcastle

Ian R. Hardcastle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5618807
    Abstract: Compounds of the general formula (1) ##STR1## wherein X represents the residue of the A, B and C rings of a asteroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R.sup.14 represents a hydrogen atom and R.sup.15 represents a hydrogen atom or an alkyl or alkoxy group of 1-4 carbon atoms, or a hydroxy or alkylcarbonyloxy group of 2 to 5 carbon atoms or R.sup.14 and R.sup.15 together represent a double bond, and R.sup.16 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, in the form of the free bases or pharmaceutically acceptable acid addition salts, are used for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent disorders such as breast cancer.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: April 8, 1997
    Assignee: British Technology Group Limited
    Inventors: Susan E. Barrie, Michael Jarman, Gerard A. Potter, Ian R. Hardcastle
  • Patent number: 5604213
    Abstract: Compounds of the general formula (1) ##STR1## wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R.sup.14 represents a hydrogen atom and R.sup.15 represents a hydrogen atom or an alkyl or alkoxy group of 1-4 carbon atoms, or a hydroxy or alkylcarbonyloxy group of 2 to 5 carbon atoms or R.sup.14 and R.sup.15 together represent a double bond, and R.sup.16 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, in the form of the free bases or phannaceutically acceptable acid addition salts, are useful for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent disorders such as breast cancer.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: February 18, 1997
    Assignee: British Technology Group Limited
    Inventors: Susan E. Barrie, Michael Jarman, Gerard A. Potter, Ian R. Hardcastle
  • Patent number: 5589500
    Abstract: Compounds of the general formula (2) ##STR1## wherein n is an integer of from 3 to 10, the iodo substituent is in the 3- or 4-position and R.sup.1 and R.sup.2, which may be the same or different, represent C.sub.1-3 alkyl, especially methyl or ethyl, groups or R.sup.l represents a hydrogen atom and R.sup.2 a C.sub.1-3 alkyl group or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached represent a saturated heterocyclic group, especially a pyrrolidino group, in the form of their free bases or pharmaceutically acceptable acid addition salts are potent anti-oestrogenic compounds useful for treatment of oestrogen-dependent cancers, especially breast cancers. Compounds where the iodine atom is radioisotopic are useful in radiotherapy or gamma ray imaging of these cancers.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: December 31, 1996
    Assignee: British Technology Group Limited
    Inventors: Karen J. Edwards, Michael Jarman, Charles A. Laughton, Stephen Neidle, Ian R. Hardcastle